About Amygdala Neurosciences
Amygdala Neurosciences is a company based in San Francisco (United States) founded in 2015 by Peter Strumph. Amygdala Neurosciences has raised $7.05 million across 6 funding rounds from investors including NIH, HHS and ABMRF/The Foundation for Alcohol Research. Amygdala Neurosciences offers products and services including ALDH2 Inhibitors. Amygdala Neurosciences operates in a competitive market with competitors including Indivior, Ethypharm, Braeburn, Cessation Therapeutics and Aelis Farma, among others.
- Headquarter San Francisco, United States
- Founders Peter Strumph
- SectorsHealthcare
- Email••••••••
- Website amygns.com
- Social X
- Legal Name Amygdala Neurosciences, Inc.
- Total Equity Funding$7.05M (USD)
in 6 rounds
- InvestorsNIH
& 3 more
Products & Services of Amygdala Neurosciences
Amygdala Neurosciences offers a comprehensive portfolio of products and services, including ALDH2 Inhibitors.
Inhibitors aimed at treating substance use disorders by reducing cravings.
Funding Insights of Amygdala Neurosciences
Amygdala Neurosciences has successfully raised a total of $7.05M across 6 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $7.05M
- Total Rounds 6
- First Round $1.45M
(Apr 2015)
- Investors Count 4
All 6 funding rounds of Amygdala Neurosciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
4 investors in total: 4 institutional.
Investors in Amygdala Neurosciences
Amygdala Neurosciences has secured backing from 4 investors, including institutional investors. Prominent investors backing the company include NIH, HHS and ABMRF/The Foundation for Alcohol Research.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Research on alcohol effects is funded by this foundation. | – | abmrf.org | Bel Air, United States | |
Drug discovery services are provided to the biopharma sector. | 1887 | nih.gov | United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - | |
Research on alcohol's health impact is conducted by NIAAA. | – | niaaa.nih.gov | Bethesda, United States |
Investor details for Amygdala Neurosciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Amygdala Neurosciences
6 people are tracked at Amygdala Neurosciences (3 in leadership, 3 in board & advisors).
| Name | Role | Group |
|---|---|---|
Peter Strumph | Founder & CEO | Leadership |
Brent Blackburn | CEO & Founder | Leadership |
Mack Mitchell | Chief Medical Advisor | Leadership |
Howard Jaffe | Director | Board & advisors |
Lou Lange | Executive Chairman & Founder | Board & advisors |
William Lee | Director | Board & advisors |
Complete people profiles for Amygdala Neurosciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Amygdala Neurosciences
3 dated milestones of Amygdala Neurosciences across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Amygdala Neurosciences is founded.
- Funding First funding round of $1.4M.
- Funding Latest funding round, Series A,.
Competitors of Amygdala Neurosciences
Amygdala Neurosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Indivior, Ethypharm, Braeburn, Cessation Therapeutics and Aelis Farma, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| indivior.com | 2014 | Richmond Hill, United States | – | 1,051 | Therapeutics for opioid addiction treatment are developed and commercialized. | |
| ethypharm.com | 1977 | Saint Cloud, France | $248.09M | – | Therapies for pain and addiction treatment are developed. | |
| braeburnrx.com | 2012 | Philadelphia, United States | $110M | – | Long-acting therapies for opioid addiction and chronic pain are developed. | |
| cessationtherapeutics.com | 2017 | San Jose, United States | $6.76M | – | Developer of immunotherapy based vaccines to manage addictions | |
| aelisfarma.com | 2013 | Bordeaux, France | $14.04M | – | Developer of small molecule drugs targeting CB1 receptor for CNS diseases | |
| titanpharm.com | 1992 | San Francisco, United States | – | 11 | A specialty pharmaceutical company developing proprietary therapeutics for select chronic diseases | |
| 4p-pharma.com | 2014 | Lille, France | $18.49M | – | French Biotech startup that develops to clinical trial stage the molecules it has in-licensed | |
| biotie.com | 1998 | Turku, Finland | $149.81M | 27 | Drugs for neurodegenerative and psychiatric disorders are developed by Biotie. | |
| kinoxistherapeutics.com | 2017 | Melbourne, Australia | $13.41M | – | Therapies for CNS disorders, including anti-addiction drugs, are developed. |
Detailed competitors of Amygdala Neurosciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Amygdala Neurosciences
The website of Amygdala Neurosciences (amygns.com) receives about 1.4K visits a month.
- Monthly visits1.4K
Latest news on Amygdala Neurosciences
Complete news archive for Amygdala Neurosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Amygdala Neurosciences
10 companies that operate in the same segment as Amygdala Neurosciences (Neurology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
MR-interfaced ultrasound devices for cancer and neurology treatments are provided. | 1999 | Tirat Carmel, Haifa District, Israel | USD 574.2 M | – | – | |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers | 2019 | San Francisco, California, United States | USD 144.72 M | – | 76 | |
Small molecule drugs for rare diseases are developed. | 1998 | South Plainfield, New Jersey, United States | USD 248.1 M | USD 1.73 B | 939 | |
Developer of small molecule therapeutics for endocrine and CNS disorders | 1992 | San Diego, California, United States | USD 10 M | USD 2.86 B | 1,800 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Amygdala Neurosciences
Amygdala Neurosciences was founded in 2015.
Amygdala Neurosciences is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Peter Strumph is the current CEO of Amygdala Neurosciences. They have also founded this company.
Amygdala Neurosciences is a funded company, having raised a total of $7.05M across 6 funding rounds to date. The company's 1st funding round was a Seed of $1.45M, raised on Apr 2015.
Amygdala Neurosciences was founded in 2015 and is based in San Francisco, United States. Focus is placed on the biotechnology sector, where therapies for substance use disorders are developed. The lead candidate, ANS-6637, functions as an aldehyde dehydrogenase (ALDH2) inhibitor targeting seeking behavior, craving, and relapse. Phase I studies have been completed, with preparations underway for a phase II trial.
Amygdala Neurosciences's top competitors include Indivior, Ethypharm and Aelis Farma.
Amygdala Neurosciences offers ALDH2 Inhibitors.
Amygdala Neurosciences has 4 investors. Key investors include NIH, HHS, ABMRF/The Foundation for Alcohol Research, and National Institute on Alcohol Abuse and Alcoholism.
Amygdala Neurosciences operates through Amygdala Neurosciences, Inc..